Tu1711 – Extended Treatment with Mirikizumab in Patients with Moderately-To-Severely Active Ulcerative Colitis: Results from a Phase 2 Trial

2019 ◽  
Vol 156 (6) ◽  
pp. S-1094
Author(s):  
William J. Sandborn ◽  
Marc Ferrante ◽  
Bal R. Bhandari ◽  
Elina Berliba ◽  
Toshifumi Hibi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Active Ulcerative Colitis ◽  
Phase 2 ◽  
Extended Treatment ◽  
Phase 2 Trial

DOP46 Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial

2019 ◽  
Vol 13 (Supplement_1) ◽  
pp. S054-S054
Author(s):  
W J Sandborn ◽  
M Ferrante ◽  
B R Bhandari ◽  
E Berliba ◽  
T Hibi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Induction Treatment ◽  
Active Ulcerative Colitis ◽  
Phase 2 ◽  
Phase 2 Trial

scholarly journals Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

2011 ◽  
Vol 140 (5) ◽  
pp. S-110 ◽  
Author(s):  
William J. Sandborn ◽  
Subrata Ghosh ◽  
Julian Panes ◽  
Ivana Vranic ◽  
Chinyu Su ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Active Ulcerative Colitis ◽  
Phase 2 ◽  
Janus Kinase Inhibitor ◽  
Phase 2 Study

scholarly journals Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis

2020 ◽  
Author(s):  
William J. Sandborn ◽  
Marc Ferrante ◽  
Bal R. Bhandari ◽  
Elina Berliba ◽  
Toshifumi Hibi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Phase 2 Trial

scholarly journals Sa1241 Pharmacology of Etrolizumab in a Phase 2 Study in Moderate-to-Severely Active Ulcerative Colitis

2014 ◽  
Vol 146 (5) ◽  
pp. S-240
Author(s):  
Caroline Looney ◽  
Franklin Fuh ◽  
Meina T. Tang ◽  
Xiaohui Wei ◽  
Mary E. Keir ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Active Ulcerative Colitis ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial

2018 ◽  
Vol 84 (6) ◽  
pp. 1136-1145 ◽  
Author(s):  
Arnab Mukherjee ◽  
Anasuya Hazra ◽  
Mike K. Smith ◽  
Steven W. Martin ◽  
Diane R. Mould ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Phase 2 ◽  
Severe Ulcerative Colitis ◽  
Phase 2 Trial ◽  
Exposure Response ◽  
Dose Ranging

Sa1125 GENE EXPRESSION (GE) VALUES IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN ULCERATIVE COLITIS (UC) CORRELATE BETTER WITH HISTOPATHOLOGY (HP) THAN ENDOSCOPY (EN) AND MAYO SCORES

2020 ◽  
Vol 158 (6) ◽  
pp. S-284-S-285
Author(s):  
Boyd Steere ◽  
Klaus Gottlieb ◽  
Jochen Schmitz ◽  
Richard Higgs ◽  
Bochao Jia ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ulcerative Colitis ◽  
Phase 2 ◽  
Phase 2 Trial

scholarly journals Corrigendum to: Randomized, Ascending Dose, Phase 2 Study of KHK4083, an Anti-OX40 Monoclonal Antibody, in Moderately Active Ulcerative Colitis

2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Jaroslaw Kierkus ◽  
Marina Pesegova ◽  
Maria Klopocka ◽  
Marija Brankovic ◽  
Noriyuki Kasai ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Monoclonal Antibody ◽  
Active Ulcerative Colitis ◽  
Phase 2 ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document